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Technical discoveries of the past 10 years in the field of molecular 
genetics have greatly expanded the horizons of industrial microbiology. 
These new techniques provide the framework for the speciality commonly 
referred to as genetic engineering. This expertise enables the researcher to 
recombine DNA (the hereditary material of the cell) in a very precise manner. 
The same techniques can be used to manufacture products which have never been 
produced before by bacteria and to manufacture products at a higher rate and 
yield than previously possible. While the controversy concerning the ethical 
issues associated with this new biochemical tool seems to have abated 
somewhat, a new concern has arisen: the role of the university in the 
commercialization of genetically engineered products which are developed on 
campus. Congress has begun to address whether commercialization will have an 
adverse impact on university biomedical research and, if so, whether there 
are mechanisms available to protect the interests of the university. 
BACKGROUND AND POLICY ANALYSIS 
The issues associated with the commercialization of university research 
recently received public attention due to the announcement by Harvard 
University that it was considering the formation of a new biotechnology 
company. On Oct. 9 ,  1980, President Derek Bok released a "Discussion 
Memorandum on Technology Transfer at Harvard University1' to the faculty. for 
its consideration. The memorandum reviewed in general terms the formation of 
a new company, in conjunction with a Harvard professor and outside venture 
capital, that would make use of patents held by the University. Harvard 
would have been given a minority share (10%) in the company, and in return 
the company would have received the rights to use the University's patents. 
The many drawbacks to such a venture were also reviewed. The memorandum drew 
extensive criticism, not only from the Harvard faculty but also from the 
media and other universiti.es. On Nov. 17, 1980, President Bok announced that 
Harvard had decided for a variety of reasons not to become a minority 
shareholder in the new biotechnology company. 
The more general issue of the relationship between commercialization and 
university research, however, is not unprecedented. Industry and the 
academic community have long recognized that they have many mutual research 
interests. During the first decades of this century, many liberal arts 
colleges were expanded and rapidly transformed into research centers for the 
emerging electrical and chemical industries. The financial ties between the 
two gradually weakened, however, following World War I1 as government 
spending for research on defense, nuclear energy, and medicine increased. In 
the mid 1950s the Federal Government provided about 55% of the support for 
university research. Industrial firms supplied 8% of the funds while the 
remaining 37% came from foundations and. State and local governments. By the 
late 1960s, the Government's share had expanded to more than 70% while 
industry's share fell to under 3%. 
Lately, however, the trend appears to be changing: industry support is 
increasing relative to that of the Federal Government. Private companies are 
searching for technological innovations to help offset growing competition 
from abroad, falling productivity, and rising energy costs. The companies 
also realize that as an adjunct to their own in-house research efforts the 
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universities are a relatively inexpensive source 'of new ideas. The 
duplication of facilities and staff available would be both wasteful and 
nonproductive. On the other hand, the universities are in need of new 
funding sources to offset shrinking enrollments, fiscal austerity, and the 
overall decline in Government support of research. 
The desire to lessen the regulations associated with the expenditure of 
Federal dollars also influences the universities to increase their reliance 
on industrial funding. The amount of time spent by researchers in compliance 
with Federal regulation has been increasing over the years. It has been 
estimated that in 1975 the faculty of Harvard University spent 80,000 hours 
filling out forms in compliance with Federal regulation. The amount of time 
is certain to increase with the implementation of Circular A-21 (released 
Feb. 26, 1979) from the Office of Management and Budget, Which requires that 
each individual scientific investigator inform the Government how he spends 
100% of his professional time, even if he is not entirely supported by 
Federal grants. Yale University recently (Mar. 22, 1982) declined a $30,000 
Federal grant when it decided not to comply with the regulation in circular 
A-21. An article in Science (1980; 210: 34-37) has estimated that Circular 
A-21 would increase the number of forms filed with Washington from 3000 to 
80,000 in the coming year. The less the dependence on Federal support, the 
greater the freedom from Federal regulation. 
There are many ways in which the academic community may participate in the 
commercialization process. Perhaps the simplest and most well established is 
to obtain exclusive licenses of university patents. In general, however, 
molecular biologists have been less active than chemists and engineers in 
obtaining patents, perhaps because their work, until recently, has lent 
itself less often to commercial applications. In addition, medical 
discoveries tended to remain unpatented since the tradition of dedicating 
health-related research to the public was generally observed. 
Another arrangement is the research partnership in which one university 
and one company work together on a single project. The Harvard 
University/Monsanto arrangement is an example of such a partnership. In 
1974, after a year and a half of negotiations, Harvard and Monsanto signed an 
agreement that over a period of 12 years Monsanto will give the University 
$23 million in research support, laboratory space construction, and endowment 
money. In return, Harvard gave Monsanto the patent rights on TAF (tumor 
angiogenesis factor), a biological substance which may be involved in the 
growth of cancerous tumors. The agreement was touted as an original, 
imaginative, and precedent setting arrangement. 
The research consortium, another collaborative effort, is becoming 
increasingly popular. It joins a single university with a group of companies 
that are interested in a common area of research. The NSF (National Science 
Foundation) introduced the idea several years ago and provided the initial 
funding for a number of programs. Among the leading industry-funded 
consortia are the MIT Polymer Processing Program and the Carnegie-Mellon 
Robotics Institute. 
A less formal version of the research consortium is the industrial 
associates (or affiliates) programs. These are short term arrangements in 
which university scientists visit companies, listen to their pr.OblemS, and 
explore approaches to solving them; these activities lay the groundwork for 
future cooperative efforts. Stanford University's biochemistry department, 
after rejecting a proposal similar to Harvard's, has decided upon an 
industrial affliates program under which companies will give the University 
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$12,000 annually. In return the companies will ' be able to send 
representatives to a seminar on the department's work, to receive one visit 
per year from a faculty member for discussions on the company's research, and 
to send a representative to Stanford to discuss this research with the 
faculty. Stanford scientists feel that this arrangement allows them to avoid 
direct commercial involvement while still seeing that research results reach 
the public domain. The University of Wisconsin runs more than 100 separate 
projects of this sort ranging from forestry and fisheries to genetic 
engineering. 
On a smaller scale than the industrial affliates/associates programs are 
the individual arrangements between a single faculty member and a particular 
company. These can range from simple consulting contracts to partial 
ownership/founder relationships. Herbert Boyer's (University of California, 
S.F.) tie with Genentech is an example in the genetic engineering field of a 
partial ownership/founder relationship. 
A few new companies have emerged which attempt to bridge the gap between 
the individual researcher or university and private venture capital. The 
much publicized DNA Science of E.F. Hutton is one such company. DNA Science 
recently (August 1981) underwent a transformation which would enable it to 
capitalize on a new tax law, P.L. 97-34, and allow the creation of a series 
of tax-advantaged partnerships. The partnerships will allow the firm's 
customers to invest in biotechnology and at the same time receive substantial 
tax benefits. P.L. 97-34, the Economic Recovery Tax Act of 1981, allows 
among other things a 25% tax credit for 65% of all of an investor's payments 
to universities for basic research. The new law also permits a larger 
deduction for charitable contributions of equipment used in scientific 
research. A similar idea has been put forth by University Genetics (or 
Ugen), a private company owned by University Patents. The parent company is 
an established business which patents technologies or inventions developed by 
university scientists and then licenses them to commercial concerns. Ugen 
emerged last October and has since raised over $30 million in capital. It . 
provides a function which allows for private investment in university 
research on genetic engineering and related topics. 
Public Law 96-517 (the Patent and '~rademark Amendment Act of 1980) gave 
organizations such as Ugen a freer hand in this type of research funding 
arrangement. The law took effect July 1, 1981, and provides a single 
Government-wide policy on the allocation of patent rights resulting from 
federally supported research with preferential benefits for universities, 
small business firms, and non-profit organizations. P.L. 96-517 requires 
that (with certain exceptions) small businesses, universities, and non-profit 
institutions be given preferential title rights to inventions made under 
federally funded R&D. Currently active grants are not affected under P.L. 
96-517, but new funding arrangements made after July 1, 1981, are covered. 
Its intent is to encourage cooperation between universities and industry by 
allowing the universities to offer future licenses in exchange for support 
even if Federal money is involved. 
Even though commercialization of academic research is not an entirely new 
issue, there has been considerable discussion and controversy over the 
entrance of biomedical research into this arena. Recent articles written on 
the subject often mention that there are many differences between the 
commercialization of physics and chemistry and what is now happening in 
biomedical research. The following are some of the differences which have 
been cited, and perhaps account for this increased controversy. 
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(1) Commercialization of biological techniques'seems to'have 
occurred much faster than previous instances in chemistry 
and physics. 
(2) The commercialization experience in biology is thought 
to involve a much broader spectrum of expertise in its 
participants than was the case previously in chemistry 
and physics. The new technology involves many individuals 
with interests in genetics, biochemistry, cell biology, 
microbiology, immunology, development, etc., while 
commercialization in the physical sciences frequently 
involves only a small number of specialists. 
(3) The range of application seems to be much greater than 
in the commercialization of discoveries in the physical 
sciences. The areas of agriculture, medicine, waste 
disposal, speciality chemicals, energy, and oil recovery 
all have the potential for future innovation by recombinant 
DNA techniques and have caught the interest of researchers 
and the private capital of industry. 
It may also be the case that since this is the first time biology has a 
major technology which is saleable, the biologists are merely experiencing 
the growing pains that physicists and chemists went through 50 years ago. 
Whether or not biology is a case of commercialization distinct from 
chemistry and physics, there have been a number of objections raised to its 
commercialization. Foremost is the issue of secrecy, which is frequently 
widespread in high1.y competitive fields of even basic research. Often a 
scientist will not discuss the results of his work until he is sure that his 
methodology and assumptions are correct. The possibility t.hat a research 
discovery may be patented is often cited as a source of secrecy. While 
patentability may contribute to secrecy over the short term, in the long run 
it eliminates the need for secrecy. After the filing date of a patent 
application, the information is at that point in the public domain and can 
then be used for discussion and noncommercial use by others. 
In the scientific community of the university, secrecy can be the source 
of friction and conflict. For example, at Harvard two researchers in the 
same department are part owners in different genetic engineering companies: 
Walter Gilbert of Biogen, a Swiss-based company, and Mark Ptashne of the 
Genetics Institute. The Harvard proposal mentioned earlier may have 
complicated matters even further if it had been approved, for the faculty 
would have included those associated with "Harvard Companyn, those with other 
industrial affiliations, and faculty members without commercial ties. 
Questions may have been raised as to whether the university administration 
would have treated certain faculty members preferentially in terms of space 
allocation, hiring, and promotion. However, as pointed out in a recent issue 
of the New England Journal of Medicine (May 14, 1981, p. 1232), the problem 
of preferential treatment is not unique to situations involving 
commercialization. Faculty salaries for an entire research department are 
sometimes drawn from grants to individual faculty members. Thus, the 
influence on appointments in a department by individuals who are capable of 
bringing with them external funding may be considerable. 
As faculty members become increasingly involved with outside companies 
(i.e., from consulting arrangements, to part ownership, to company officers), 
critics question whether they will be able to remain equally dedicated to 
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campus activities such as teaching undergraduate students and guiding the 
research efforts of graduate students. The development of a new company is 
likely to require much more time than a consulting agreement. They also 
question whether it is wise for graduate students to work on projects related 
to their thesis advisor's industrial interests, and whether commercialization 
may cause a shift in the nation's research from basic to applied biomedical 
research. Will graduate students receive a well rounded education if their 
graduate school experience is in applied research? Would they now choose 
industry over teaching and basic research? Would a shift from basic to 
applied biomedical research be in the country's best interests? 
New biotechnology companies emerge every month, and each seeks to recruit 
the best possible staff. These companies are prepared to pay salaries much 
higher than the academic community. Thus commercialization is contributing 
to the phenomenon known as "brain drain." One writer has compared it to the 
American Indians' being forced to consume their seed corn, and therefore 
dooming the fate of the following year's crop (Science, July 10, 1981). If 
the university faculties are being recruited for industry jobs, who will 
remain to teach the next generation of scientists? The Harvard proposal and 
companies such as Ugen and DNA Science were designed to circumvent this 
problem. However, the Harvard proposal had problems which made it 
unacceptable to the faculty, and DNA Science has had preliminary troubles in 
starting up its new form of investment company. It remains to be seen 
whether companies such as Ugen and DNA Science will have an effect on the 
"brain drain" phenomenon. 
One of the qualities which university researchers take pride in is their 
objectivity: the ability to be impartial When making statements on subjects 
of public interest. Recently, however, the credibility of university 
scientists associated with industry has fallen into question. During the 
Supreme Court hearing on the patentability of a genetically engineered 
microorganism, reference was made to Walter Gilbert's (Harvard/Biogen) views 
on the safety of recombinant DNA research. The United States Solicitor 
General argued that because of Dr. Gilbert's involvement with a biotechnology 
company, "he is thus hardly an impartial observer in the debate 'over the 
biohazards associated with genetic engineeringw (Science, 1980, 208:688-692). 
(Dr. Gilbert has recently announced that he will resign from Harvard as of 
July 1, 1982, rather than relinquish his position in the company he helped 
found. ) 
A final objection, which also was a major topic in a recent (June 8, 9, 
1981) congressional hearing, is whether the American public is indirectly 
funding industry by allowing the commercialization process to continue. 
Chairman Albert Gore of the House Subcommittee on Oversight and 
Investigations has asked if industry is "skimming off the cream produced by 
decades of taxpayer funded work." A case in point is the Massachusetts 
General Hospital (MGH) arrangement with Hoechst A.G., a West German chemical 
and pharmaceutical company. Hoechst agreed to pay MGH $50 million over the 
next 10 years and in return is receiving the first options rights for 
licenses from any projects which the company has funded. The licenses will 
be negotiated on a case by case basis, reflecting the financial contribution 
of the company to the specific patent being discussed. Hoechst cannot 
specify what type of work it would like MGH to perform, but it may refuse to 
support specific research projects. In addition, Hoechst is allowed to send 
individuals to MGH for training and consultation with the Hospital's faculty. 
The individual scientists at MGH will be allowed to publish when they choose, 
provided that hospital authorities are informed in advance. There will also 
be no restrictions on collaboration with other scientists. The MGH/Hoechst 
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contract was the subject of a General Accounting Office (GAO) investigation 
at the request of the House Science and Technology Investigations and 
Oversight Subcommittee. The GAO report indicates that it should be possible 
for MGH to separate research funded by Hoechst from federally funded 
research. According to the report, however, difficulties may arise when 
there is doubt over whether a patent exploited by Hoechst has been supported 
exclusively by the German company. In addition to the $50 million from 
Hoechst A.G., MGH is reportedly also receiving $15 million from two 
philanthropists, Arthur 0. and Gullan M. Wellman, for the construction of 
new laboratory facilities. 
Massachusetts General Hospital is not the only biomedical research 
facility with ties to industry. In addition to the funds Harvard is 
receiving from Monsanto, Dupont recently announced (June 1981) a $6 million 
grant for basic research in molecular genetics. The research will be 
directed by Philip Leder, formerly of NIH, who recently joined the Harvard 
Medical School as chairman of the newly formed Department of Genetics. The 
grant will be spread over a five year period with a $2 million payment in 
July 1981 and annual payments of $1 million through 1985. 
Some further reported arrangements are as follows: 
(1) Phillips Petroleum invested $10 million in a joint venture with the 
Salk Institute to develop commercial applications of basic research from the 
Institute's laboratories. 
(2) The new French biotechnology company, Transgene, has distributed 
equity to the Pasteur Institute in Paris and to the University of Strasbourg. 
England's national biotechnology company, Celtech, will be sh sharing its 
profits and research results with the Medical Research Council Molecular 
Biology Laboratory at Cambridge. 
(3) At the University of Wisconsin, two scientists with research interests 
in agriculture have formed consulting/partnership associations with two 
biotechnology companies. Winston J. Brill is associated with Cetus, a firm 
near San Francisco which is in the process of setting up a Madison, 
Wisconsin, laboratory. Timothy C. Hall is working with Agrigenetics. 
(4) Several members of the molecular biology and microbiology department 
at Tufts University medical school have formed a research consulting 
partnership separate from the University. 
(5) The University of California, Davis signed an agreement with Allied 
Chemical for a $2.5 million grant over the next five years. Raymond C. 
Valentine, a plant geneticist at Davis, played an instrumental role in the 
contract negotiations which lasted for about two years. While the 
negotiations were taking place, Valentine proceeded to form a non-profit 
institution called Cal Gene which was eventually transformed into Calgene, a 
private corporation. Shortly after the grant negotiations were finalized, 
Allied announced that it had purchased a 20% equity interest in Calgene. To 
avoid possible charges of conflict of interest, Valentine agreed to cease his 
involvement with the University's $2.5 million grant. A University committee 
is in the process of preparing a detailed set of recommendations, to be 
released in June, defining University-industry interactions. 
(6) Washington University in St. Louis and Mallinckrodt Inc., a chemical 
manufacturer, have signed a $3.88 million agreement for genetic research. 
The research involves the production of monoclonal antibodies from 
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artifically created cells called hybridomas. Mallinckrodt will have the 
option to license results from research it sponsors and will pay royalties to 
the University. The scientists will be free to publish their research 
findings and to exchange new cell lines and antibodies with outside 
scientists. Washington University has also signed a $1.8 million agreement 
with Monsanto Corp. to produce monoclonal antibodies. 
(7) The Massachusetts Institute of Technology (MIT) accepted (12/4/81) a 
gift of $7.5 million and $120 million for the establishment of the Whitehead 
Institute for Biological Research. Nobel laureate David Baltimore will 
become the Institute's director while continuing as a professor of Biology at 
MIT. The money for both gifts was donated by Edwin C. Whitehead of 
Connecticut who recently sold Technicon, a company he founded in 1939, to 
Revlon for $400 million. 
(8) Yale University and Celanese Corporation, a chemical manufacturer, 
announced the signing of a three-year $1.1 million research contract on Feb. 
17, 1982. Celanese is interested in learning how to use naturally occurring 
enzymes in the manufacture of chemicals and fabric. Yale has also formed an 
Office of Cooperative Research in an effort to tighten ties between the 
University and corporations. 
(9) The Alberta Research Council, an agency of Alberta province, has 
signed a 4-year, $8 million agreement with Biologicals, Inc. for the use of 
enzymes in industrial applications. Work on the project will be conducted on 
the campus of the University of Alberta in Edmonton. 
(10) Dr. Herbert Boyer', director and vice president of Genentech, a 
genetic engineering company, still retains his faculty position at the 
University of California, San Francisco. 
(11) Cold Spring Harbor Laboratories, directed by Dr. James Watson, is , i n  
the process of setting up a corporation which will help commercialize the 
laboratories' scientific discoveries. The corporation will operate 
separately from the Laboratory. 
(12) The University of California at Berkeley, Stanford, and Engenics, a 
biotechnology concern, have received financial backing from six major 
corporations: General Foods Corp.; Bendix Corp.; Elf Technologies unit of 
Societe Nationale; Elf Aquitaine; Koppers Corp.; Mead Corp.; and Maclaren 
Power and Paper Co., a subsidiary of Noranda, Mines Ltd. The universities' 
shares of the research funding will be channeled through a new cooperative 
nonprofit center for biotechnology research., The center will hold a 30% 
equity share of Engenics and will channel any capital appreciation or stock 
dividends from the new company back into basic research at the two 
universities. The universities will cooperate in research with Engenics, 
which received $7.5 million from the six corporations. 
(13) Johns Hopkins University and Hybritech, a San Diego biotechnology 
firm, signed an agreement Feb. 12, 1982, to develop and evaluate radioactive 
antibodies for cancer treatment. Hybritech will provide the antibodies Which 
Hopkins' oncology center will use in clinical trials. 
(14) The Rockefeller University and Monsanto Co. have announced (March 
1982) a five-year $4 million agreement under which Monsanto will support 
basic research in plant molecular biology at the University. 
(15) Dupont and the University of Maryland have an agreement to produce 
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interferon in Bacillus subtilis, a non-pathogenic soil bacterium. 
(16) FMC Corporation has given (June 1981) Frederick M. Ausubel of Harvard 
University $190,000 for each of the next 3 years for research on nitrogen 
fixation in plants. 
(17) A.M. Chakrabarty of the University of Illinois has agreed to a 2-year 
Contract with Petrogen for the development of genetically engineered bacteria 
for enhanced oil recovery. 
(18) Monsanto Co. and Washington University announced on June 3, 1982, a 
$23.5 million 5-year biomedical research contract for study of the breakdown 
of genetic functions and cell communication associated with several diseases. 
Universities are beginning to set up their own conflict-of-interest-rules. 
The University of California, Davis, mentioned above, is one example. In 
late September 1981, the faculty council of Harvard University agreed to 
recommend to the full faculty a new set of procedures which would establish 
the "Faculty Committee on Conflicts of Interest." If adopted, the new rules 
would require that faculty members notify the Conflicts of Interest Committee 
about any outside commitments. The rules would also limit such commitments 
to 20% of the faculty member's time. Stanford University already has a 
formal set of guidelines due to its faculty's involvement with the 
microelectronics industry. However, Stanford is in the process of developing 
new proposals to tighten up the existing guidelines. In addition, on Mar. 
27, 1982, the presidents of five leading U.S. universities (Stanford, Harvard 
MIT, California Institute of Technology, and the University of California 
system) attended a conference in Watsonville, California, with scientists and 
business leaders on the commercial use of university scientific research. 
The conference produced a 10-page statement containing recommendations for 
universities that have recently developed relations with industry. 
Meanwhile, the House Science and Technology Investigations and Oversight 
Subcommittee has asked the National Academy of Scien.ces and the American 
Association of Universities to draft a code of ethics for financial 
arrangements between universities and industry. 
LEGISLATION 
P.L. 97-34, H.R. 4242 
The Economic Recovery Tax Act of 1981. Allows, among other things, a 25% 
tax credit for 65% of all a firm's payments to universities to perform basic 
research. Also permits a larger deduction for charitable contributions of 
equipment used in scientific research. Introduced July 23, 1981. Passed 
House July 29, Senate July 31. Signed into law Aug. 13, 1981. 
H.R. 1937 (Kastenmeier) 
Amends the patent law to extend the term of patents which encompass 
specified products over a method for using a product any of which are subject 
to certain nonpatent regulatory review periods. Introduced Feb. 18, 1981; 
referred to Committee on Judiciary. 
H.R. 4326 (LaFalce) 
Amends the Small Business Act to require Federal agencies to establish 
small business innovation research (SBIR) programs. Introduced July 29, 
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1981; referred to Committee on Small Business. Reported with amendment 
(H.Rept. 97-349) NOV. 20, 1981. Referred sequentially to several committees. 
Passed House, amended, June 23, 1982. Measure laid on table in House; S. 881 
passed in lieu June 23, 1982. 
H.R. 5919 (Waxman) 
Amends the Public Health Service Act to revise and extend the authorities 
under that Act relating to national research institutes. Also, requests a 
report from the Institute of Medicine on the effects of commercialization on 
biomedical research. Introduced Mar. 22, 1982; referred to Committee on 
Energy and Commerce. 
S. 255 (Mathias et al.) 
Amends the patent law to extend the terms of patents which encompass 
specified products or a method of using a product, any of which are subject 
to certain nonpatent regulatory review periods. Introduced Jan. 27, 1981; 
referred to Committee on the Judiciary. Reported (S.Rept. 97-138) June 16, 
1981; passed Senate amended July 9 ,  1981; referred to House Committee on the 
Judiciary July 13, 1981. 
S. 881 (Rudman et al.) 
Amends the Small Business Act to require Federal agencies to establish 
small business innovation research (SBIR) programs. Introduced Apr. 7, 1981; 
referred to Committee on Small Business. Reported with amendment (S.Rept. 
97-194) Sept. 25, 1981; passed Senate Dec. 8, 1981. Passed House, amended, 
in lieu of H.R. 4326 June 23, 1982. 
HEARINGS 
U.S. Congress. House. Committee on Energy and Commerce. 
Subcommittee on Health and the Environment. Small Business 
Innovation Development Act, H.R. 4326. 
Hearings, 97th Congress, 2nd session. Feb. 2, 1982. 
(not yet printed) 
U.S. Congress. House. Committee on the Judiciary. Subcommittee 
on Courts, Civil Liberties and the Administration of Justice. 
Patent Term Restoration Act, S. 255 and H.R. 1937. 
Hearings, 97th Congress, 1st session. July 22; Sept. 30; 
Oct. 1, 7; Nov. 5, 12, 18, 1981. (not yet printed) 
U.S. Congress. House. Committee on Science and Technology. 
Small Business Innovation Development Act, H.R. 4326. 
Hearings, 97th Congress, 2nd session. Jan. 26-28, 1982. 
(not yet printed) 
U.S. Congress. House. Committee on Science and Technology. 
Investigations and Oversight. Subcommittee on Science, Research 
and Technology. University/industry cooperation in biotechnology. 
Hearings, 97.th Congress, 2d session. June 16 and 17, 1982. 
(not yet printed) 
U.S. Congress. House. Committee on Science and Technology. 
Subcommittee on Investigations and Oversight. Subcommittee 
on Science, Research and Technology. Commercialization of 
academic biomedical research. 
Hearings, 97th Congress, 1st session. June 8 and 9, 1981. 
Washington, U.S. Govt. Print. Off., 1981. 166 p. 
U.S. Congress. Senate. Committee on Small Business. Subcommittee 
on Innovation and Technology. Small Business Innovation 
Research Act, S.881. 
Hearings, 97th Congress, 1st session. July 15-16, 1981. 
(not yet printed) 
U.S. Congress. House. Committee on Veterans' Affairs. 
Subcommittee on Hospitals and Health Care. Small 
Business Innovation Development Act, H.R. 4326. 
Hearings, 97th Congress, 2nd session. Jan. 27, 1982. 
(not yet printed) 
CHRONOLOGY OF EVENTS 
03/27/82 -- The presidents of five leading U.S. universities 
(Stanford, Harvard, MIT, California Institute of 
Technology, and the University of California system) 
attended a conference in Watsonville, California, 
with scientists and business leaders on the commercial 
use of university scientific research. 
01/06/82 -- The American Association for the Advancement of Science 
(AAAS) held a session entitled wCommercial Genetic 
Engineering: Impacts on Universities and Nonprofit 
Institutions." 
12/04/81 -- Massachusetts Institute of Technology (MIT) accepted 
gifts of $7.5 million and $120 million from E.C. 
Whitehead for the establishment of the Whitehead 
Institute for Biological Research. 
10/16/81 -- The General Accounting Office published a legal 
analysis of the research contract between 
Massachusetts General Hospital and Hoechst A.G., 
a West German chemical company. 
08/13/81 -- H.R. 4242, the Economic Recovery Tax Act, was signed 
into law (P.L. 97-34). Allows tax credits for basic 
research. 
07/10/81 -- The editorial "The fate of the seed cornm appeared in 
Science. Highlighted the impact of losing experienced 
university professors to the biotechnology industry. 
06/29/81 -- Dupont announced a $6 million grant to Harvard Medical 
School in support of basic research in molecular 
genetics. 
06/08-09/81 -- House Science and Technology Subcommittee on 
Investigations and Oversight and Subcommittee on 
Science, Research and Technology held hearings on the 
"Commercialization of Academic Biomedical Research." 
06/08/81 -- The advisory committee to the director of NIH held a 
meeting which discussed whether the quality of basic 
research is compromised by industrial support. 
05/20/81 -- The West German Chemical firm, Hoechst A.G., announced 
a $50 million grant to Massachusetts General Hospital 
to support basic research in molecular genetics. 
12/12/80 -- H.R. 6933, the Patent and Trademark Amendment 
Act was enacted (P.L. 96-517), providing a new policy for the 
allocation of patent rights resulting from 
federally-supported research. 
11/17/80 -- Harvard President Derek Bok announced that Harvard 
University would not become involved in a new 
genetic engineering company. 
02/00/75 -- Monsanto announced a $25 million grant to Harvard 
University in support of investigations in molecular 
biology. 
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